Technically Speaking, page-1714

First 1714 Last

Share
Profile

Follow
stoneral33

2,853 Posts.

661

19/02/20

19:54

Post #: 43030186
Share

Originally posted by said_smitty: ↑

Why would he buy more? They needed cash and they looked for investors and BP took interest and after months and months of tests he saw potential and had given them cash at a premium what he thought it was worth at the current stage, he also become a director and worked his way to the top, he has set up a register on the OTC market and the DTC which would be soon, we are just about ready to commercialise this product and BP is building a solid foundation so when this does get commercialised it will reward shareholders handsomely. He doesn’t care about the short term or the immediate term he has one goal and that’s to commercialise this product. I don’t see why people fuss that they are not doing much when they are working on the product to make it better and working on commercialisation. I read a book from an investor back in the 50s who supposedly never made a loss and never sold a stock unless his reason for holding changed, he brought into a spec stock that had an exciting product and payed $5 a share and years went by he waited for commercialisation it went to $4.$3, $2, $1 even and at the end his patience was rewarded and he made ridiculous amounts of money. Don’t count your chickens before you hatch.

Expand

"OTC market" NOT ONE SHARE HAS BEEN TRADED
" we are just about ready to commercialise this product" WHAT PRODUCT? WHEN?
Better investments elsewhere atm imho GLTA

PO3 Price at posting: $2.50 Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 1714 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Technically Speaking, page-1714

Top Stories

Monash IVF shares cater 25% – Disaster or deep-value play?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News